July 9, 2020 -- Life sciences company LGC has acquired the Native Antigen Company (NAC), an Oxford, U.K.-based supplier of infectious disease antigens and antibodies.
NAC's portfolio includes 60 viral and infectious disease products, including pathogen receptors, virus-like particles and antibodies for immunoassay technologies, and vaccine development and quality control solutions. The global supplier also offers antigens for SARS-CoV-2 to help researchers respond to the COVID-19 pandemic.
The acquisition will bolster LGC's product offerings in the IVD market, according to the company. LGC's existing IVD offerings include quality assurance tools, immunoassay reagents, disease-state plasma, and probes and primers for molecular diagnostics.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current